Teva Forecasts 2024 Adjusted EPS Of $2.40-$2.50 Versus Prior Guidance Of $2.30-$2.50 And Consensus Of $2.45

Benzinga
2024-11-06

Outlook for 2024 Non-GAAP Results

$ billions, except EPS or as notedNovember 2024 OutlookJuly 2024 OutlookFebruary 2024 Outlook
Revenues*$16.1 - $16.5$16.0 - $16.4$15.7 - $16.3
AUSTEDO ($m)*~1,600~1,600~1,500
AJOVY ($m)*~500~500~500
UZEDY ($m)*~100~80~80
COPAXONE ($m)*~500~450~400
Operating Income4.2 - 4.54.1 - 4.54.0 - 4.5
Adjusted EBITDA4.7 - 5.04.6 - 5.04.5 - 5.0
Finance Expenses ($m)~1,000~1,000~1,000
Tax Rate14% - 17%14% - 17%14% - 17%
Diluted EPS ($)2.40 - 2.502.30 - 2.502.20 - 2.50
Free Cash Flow**1.7 - 2.01.7 - 2.01.7 - 2.0
CAPEX*~0.5~0.5~0.5
Foreign ExchangeVolatile swings in FX can negatively impact revenue and income 

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10